Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19

Coronavirus disease (COVID)-19 is the leading global health threat to date caused by a severe acute respiratory syndrome coronavirus (SARS-CoV-2). Recent clinical trials reported that the use of Bruton’s tyrosine kinase (BTK) inhibitors to treat COVID-19 patients could reduce dyspnea and hypoxia, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaliamurthi, Satyavani, Selvaraj, Gurudeeban, Selvaraj, Chandrabose, Singh, Sanjeev Kumar, Wei, Dong-Qing, Peslherbe, Gilles H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267665/
https://www.ncbi.nlm.nih.gov/pubmed/34209188
http://dx.doi.org/10.3390/ijms22137071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267665/
https://www.ncbi.nlm.nih.gov/pubmed/34209188
http://dx.doi.org/10.3390/ijms22137071

Ejemplares similares